Barrier Therapeutics To Submit Amended J&J Miconazole Diaper Rash NDA
This article was originally published in The Pink Sheet Daily
Barrier plans to submit the application by year-end, seeking a narrower indication than the original Johnson & Johnson NDA. Barrier's Phase III study of Zimycan in Candida-associated diaper dermatitis was designed to address FDA concerns over the scope and definition of the non-specific diaper dermatitis indication J&J had pursued for the ointment, then called Pediastat.
You may also be interested in...
FDA may be evaluating the future of accelerated approval, but data from the Pink Sheet’s Performance Tracker shows growth in the submissions and approvals over the past five years.
Keeping Track Of US FDA Decisions: COVID-Induced Complete Response Letter For Contepo; Safety Sinks Abicipar Pegol; Approvals For Fintepla and Gimoti
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Pink Sheet Podcast: New Drug Submissions Lag, More US FDA Emergency Use Authorizations On The Way, BsUFA Revenue Misses Estimates
Pink Sheet reporter and editors discuss the lower application submission rate, another EUA for a potential coronavirus treatment, and the biosimilar user fee program missing revenue estimates again.